A recent report identified CaMKv as a potential immunotherapeutic target in MYCN-amplified neuroblastoma, due to its inordinately high expression in these tumors compared to normal human tissues (Sussman et al., 2020). The gene discussed is CAMKV; the disease is neuroblastoma.